Introduction {#s1}
============

Poly(ADP-ribose)polymerase-1 (PARP1) is a 116 kDa DNA repair enzyme with nuclear concentrations ranging from 2 × 10^5^ to 1 × 10^6^ enzymes/nucleus in eukaryotic cells ([@B73]; [@B50]). Within 30 seconds of the advent of DNA damage, PARP PARylates itself, activating the enzyme and leading to a 500-fold increase in its activity over basal levels ([@B12]; [@B6]; [@B45]; [@B48]; [@B69]). Unsuccessful PARP1 mediated repair can result in cell death through multiple pathways, including apoptosis ([@B56]), ATP depletion ([@B76]), parthanatos ([@B28]), and mitotic catastrophe ([@B113]).

Over the past decade, inhibitors of PARP have emerged as a common monotherapy for certain subtypes of breast and ovarian cancers ([@B122]). Moreover, preclinical data has demonstrated that PARP inhibition can increase radiosensitivity in cancer cells ([@B137]). The efficacy of combination therapies employing PARP inhibitors and external beam radiation has been demonstrated in the clinic, and several phase I clinical trials based on this approach have been completed at the time of writing (NCT00770471, NCT00649207, NCT01264432, NCT01477489, NCT01514201, NCT01657799), with results being available for some of them ([@B109]; [@B122]; [@B32]). The use of PARP inhibitors as scaffolds for radiopharmaceuticals has also blossomed in recent years ([@B52]; [@B110]; [@B19]; [@B20]; [@B53]; [@B103]; [@B75]; [@B97]). To wit, several clinical trials of PARP-inhibitor-based diagnostic imaging agents are currently in progress or have been completed (\[^18^F\]FluorThanatrace ([@B83]), PARPi-FL ([@B63])), and \[^18^F\]PARPi ([@B112])) and a number of therapeutic radiopharmaceuticals based on PARP inhibitors have been employed in preclinical animal models ([@B61]; [@B83]; [@B111]).

Mechanism of PARP Inhibition {#s2}
============================

DNA Binding {#s2_1}
-----------

PARP1 is composed of six domains. Moving from the N-terminus to the C-terminus, the enzyme contains three zinc fingers (Zn1, Zn2, Zn3), one domain for auto-poly(ADP-ribose)ylation (autoPARylation; AD) that contains a breast cancer 1 protein (BRCT) motif on the c-terminus of the domain, one domain that interacts with open chromatin (WGR) ([@B5]; [@B125]), and one domain associated with the enzyme's catalytic activity (CAT) comprised of a helical subdomain (HD) and a conserved ADP-ribosyl transferase subdomain (ART). Zn1 and Zn2 are homologous domains that recognize and bind DNA, though it has been shown that the enzyme can bind DNA with only one of these two domains ([@B68]) ([**Figure 1**](#f1){ref-type="fig"}). Taken together, the Zn fingers engage not specific sequences of DNA but rather structural motifs such as blunt ends, single strand breaks (SSBs), double strand breaks (DSBs), 3′ single-base overhangs, and long overhangs ([@B26]; [@B27]; [@B96]). It is important to note that in each of these cases, PARP1 binds to the irregular angle in the broken DNA strand, not the exposed nucleotides ([@B71]). Furthermore, each Zn finger seems to play a particular role in a different aspect of the enzyme's function. For example, Zn1 is responsible for binding DSBs, interacting with the catalytic domain, and activating PARP1. Zn2 seems to be responsible for the recognition of SSBs. ([@B37]). Zn3 has been shown to play a critical role in protein--protein interactions during DNA-dependent autoPARylation by initiating hydrolysis of the NAD^+^ substrate ([@B66]; [@B133]). Unlike Zn1 and Zn2, Zn3 is not required for DNA activation, though it does mediate PARP1--chromatin interactions ([@B67]; [@B133]).

![Schematic representation and crystal structure of PARP1 domains and subdomains. **(A)** Schematic representation of human PARP-1 domains and subdomains. A BRCA C-terminus (BRCT) fold is located within the region of PARP-1 that is primarily targeted for automodification. The catalytic domain is composed of an alphahelical subdomain (HD) and an ADP-ribosyl transferase subdomain (ART). **(B)** Crystal structure of the PARP-1/DNA structure. Zn1, Zn3, and WGR-CAT are shown as surfaces. The arrow indicates the location of the PARP-1 automodification region near the catalytic active site. From [@B69]. Reprinted with permission from AAAS. \[PDB code 4DQY, ([@B69])\].](fphar-11-00170-g001){#f1}

Single and Double Strand DNA Repair {#s2_2}
-----------------------------------

The complete mechanisms of poly(ADP-ribosyl)ation by the PARP family of enzymes and its role in DNA repair and regulation warrants further investigation ([@B2]). One proposed hypothesis is the homodimerization of PARP1 after recruitment to the side of DNA damage to begin autoPARylation and the repair process ([@B9]; [@B10]; [@B79]; [@B80]; [@B81]). PARP1 has been shown to dimerize in its active form in solution which, greatly increased its specific activity (pmol of product/min per pmol of enzyme) ([@B10]). PARP1 dimerization was also confirmed by dynamic light scattering ([@B132]). The rate of automodification is a function of PARP concentration consistent with second order kinetics. The rate kinetics suggest a dimerized model in which two PARP1 enzymes initialize PARylation, each with an active NAD^+^ binding site ([@B79]; [@B80]; [@B81]). Interestingly, an earlier study supports a model where optimal enzyme activity and PAR chain formation occur in a PARP1:DNA binding stoichiometry of 2:1 where one PARP1 enzyme is catalytically active and the other PARP1 acts as a receptor for PARylation ([@B93]). This model is supported by the crystal structure of the Zn1 and Zn2 domains from separate PAPR1 enzymes in a dimer, complexing damaged DNA ([@B3]). Another study found the 5′-recessed structure of DNA will recruit PARP1 in a 2:1 PARP1:DNA stoichiometry ([@B96]). Once dimerized, PARylation and autoPARylation are initiated. AutoPARylation takes place on glutamate and lysine residues found in the AD ([@B5]; [@B133]). This domain is also the site of protein--protein interactions (WGR) with the downstream protein targets of PARP1 ([@B133]). However, in the absence of an AD domain, PARP1 can still PARylate other proteins ([@B5]).

There are several proteins which can be modified with potentially large, negatively charged PAR chains, which have been found to be between 1 and 200 units long ([@B46]). It has been suggested that as the length of the PAR chain increases the affinity of PARP1 for DNA decreases, mostly due to its highly negative charge, allowing PARP1 to release the DNA and leave space for other DNA repair proteins to bind ([@B90]; [@B100]; [@B129]; [@B127]). The PAR chain can be hydrolyzed to shorter PAR chains, mono(ADP-ribose) by ADP-ribose hydrolase (ARH3) or PAR glycohydrolase (PARG) ([@B91]; [@B85]). When ARH3 or PARG cleaves the first ADP-ribose in a PAR chain from PARP it reestablishes the enzyme's ability to recognize and bind DNA damage, essentially "resetting" the PARP ([@B107]).

The most direct use of the PAR chain is as energy in the form of ATP when the cell is experiencing decreased levels of ATP ([@B95]; [@B136]). It is known that DNA damage leads to rapid depletion of ATP reserves in the cell ([@B118]). This lends to the hypothesis that one role of PARP is to provide ATP from NAD^+^ for the ligation step in the BER pathway, which is favored in times of ATP depletion ([@B95]; [@B136]).

The PAR chain has been reported to have the potential to recruit an array of different proteins ([@B107]). When interacting with acceptor proteins, the PAR chains can modulate localization, function, and structure ([@B64]; [@B65]). Aside from autoPARylation, target proteins for PARylation by PARP1 include other DNA repair proteins, transcription factors, histones, and chromatin modulators ([@B26]; [@B48]). One of the PARylation targets during DNA damage repair is H1, whose targeting results in the relaxation of the chromatin super structure and recruitment of repair proteins such as XRCC1 ([@B36]; [@B92]). XRCC1 binds directly to the PAR chain, whereas other repair proteins interact with mediating proteins that in turn bind PAR ([@B107]).

Necessary, additional interactions between DNA repair proteins occur through a BRCA1 carboxy-terminal (BRCT) repeat motif found in many other proteins involved in DNA damage repair ([@B55]). This domain, containing a conserved ADP binding sequence comprised of 20 amino acids, has been identified and found to overlap with domains in many proteins associated with DNA binding, nuclear localization, nuclear export, protein degradation, and protein--protein interaction ([@B98]). Two enzymes essential to HR, ataxia telangiectasia-mutated (ATM) and mitotic recombination 11 (MRE11) are signaled through PAR as well ([@B45]; [@B121]).

Synthetic Lethality {#s2_3}
-------------------

Exploiting synthetic lethality---a relationship between two cellular mechanisms wherein the functional loss of one is survivable but the loss of both is lethal---was proposed as a treatment for cancer almost a quarter of a century ago ([@B47]). This strategy was validated during the phase I trial of the PARP1/2 inhibitor olaparib, when the majority of patients with BRCA1/2 mutations saw a benefit from PARPi intervention ([@B41]). In 2014, olaparib received FDA approval for treatment of advanced ovarian cancer ([@B60]).

When the homologous recombination (HR) pathway is compromised, inhibition of the remaining PARP-dependent BER pathway can be lethal to cells, although the exact mechanism is not entirely understood ([@B49]). Presently, the model for PARPi-mediated synthetic lethality is that an inhibitor will bind a DNA-bound PARP enzyme, preventing it from PARylating proteins or dissociating from the DNA. These lesions, caused by trapped PARPs, accumulate and prevent DNA repair and replication, causing cytotoxicity ([@B87]; [@B88]; [@B101]). Likely, the HR pathway fails in BRCA-deficient cells due to loss of function of BRCA1/2, causing the cells to rely upon BER to repair damaged DNA ([@B119]). The BRCA1 and BRCA2 genes code for the eponymous tumor-suppressing proteins essential to the HR repair pathway ([@B108]). Loss of function of one of these genes *via* mutation is associated with a high risk of breast and ovarian cancer ([@B84]; [@B139]). These types of BRCA1/2 negative cancers are naturally sensitive to PARP inhibitors ([@B14]; [@B39]; [@B70]; [@B106]; [@B41]; [@B38]).

While synthetic lethality *via* PARP inhibitors is frequently associated with BRCA1/2 mutations in the literature, many genes play crucial roles in various stages of the HR repair pathway ([@B22]; [@B51]). An example of how PARP inhibitors can be lethal to HR-deficient cells is their effect on XRCC1-deficient cells. An increased amount of SSBs were detected when XRCC1-deficient cells were treated with a PARP inhibitor ([@B119]). Certain tumors arising from hereditary cancers that share an HR-deficient phenotype, not just BRCA deficiency, are sometimes described by the term "BRCAness." This includes any mutation that would affect replication fork stability, or any genes involved in the HR pathway, for example ATM, ATR, FANC, or PALB2 ([@B130]; [@B78]; [@B72]). There is evidence of BRCAness and PARP inhibitors inducing synthetic lethality in cancers that are known to have HR-deficient pathways, such as high-grade serous ovarian cancer (HGS-OVCa), advanced prostate cancer, and pancreatic cancers ([@B11]; [@B18]; [@B77]; [@B134]; [@B72]).

The first evidence of PARP inhibition inducing lethality appeared in the 1970s when NAD^+^ analogs were used to bind PARP1 in combination with a genotoxic agent ([@B13]; [@B123]; [@B102]). At the time of writing, four therapeutic PARP inhibitors have been approved by the FDA (olaparib, rucaparib, niraparib, and talazoparib) and four more are in various stages of clinical trials (veliparib, E7016, CEP-9722, BGB-290; NCT01827384, NCT01605162, NCT01345357, NCT03150810, respectively).

Increased Genomic Instability After PARP Inhibition {#s2_4}
---------------------------------------------------

Originally, the mechanism proposed for PARP-inhibitor-mediated synthetic lethality was the accumulation of DSBs produced when a replication fork failed after encountering an inhibited PARP bound to an SSB ([@B39]). There is evidence that cells undergoing PARP inhibition contain no significant increase in SSBs ([@B44]; [@B119]). PARP knockout cells and PARP knockdown cells contain no higher level of SSBs than wildtype cells ([@B40]). These findings suggest alternate explanation of PARP inhibitor-mediated synthetic lethality.

PARP more directly affects the genome through PARylating histones and other nuclear proteins to unwind the chromatin structure ([@B29]; [@B4]). An increased level of biomarkers of genomic instability, such as DNA strand breaks, gene amplification, DNA recombination, and SCE were found in cells with decreased PARP activity after treatment with DNA-damaging agents. These findings were made using PARP inhibitors, PARP knockout models, and asRNA models ([@B54]; [@B135]; [@B30]; [@B114]).

These results lead to the hypothesis that when HR and BER pathways are inaccessible to cells, they rely on non-homologous end joining (NHEJ). HR and BER are conservative DNA repair methods, maintaining the original DNA sequence that was damaged. When HR is not an option for the cell, it has to rely on BER and NHEJ. NHEJ is a non-conservative repair pathway because it will excise the damaged DNA, leading to genomic instability ([@B86]; [@B131]). It has been shown that NHEJ is promoted in cells with defective HR pathways after treatment of PARP inhibitors. Also, resistance to PARP inhibitors is acquired when the NHEJ pathway is inhibited ([@B94]). These findings indicate that PARP-inhibitor-induced lethality can also be attributed to genomic instability as a result of the NHEJ pathway in non-irradiated situations.

PARP Trapping {#s2_5}
-------------

PARP trapping is the formation of a PARP--DNA complex through inhibition of DNA-bound PARP. PARP--DNA complexes were detected in cell lines treated with olaparib and rucaparib ([@B87]; [@B88]). PARP inhibitors prevent PARP from synthesizing PAR chains by competitively binding PARP's natural substrate, NAD^+^.

Interestingly, inhibiting PARP is more cytotoxic than the absence of PARP itself ([@B124]). One hypothesis for this effect might be due to replication fork stalling and subsequent collapse, a mechanism shared with topoisomerase I (TOP1) and TOP1 inhibitors. Further evidence of PARP trapping and collapsing replication forks is PARP1's role in restarting stalled replication forks, a task prevented by PARP inhibitors ([@B140]; [@B15]). This mechanism sheds some light on the lethality of PARP inhibitors in cells with and without BRCA mutations ([@B120]).

The efficacy of PARP trapping was shown to be independent of the half-maximal inhibitory concentration (IC~50~) of the PARP inhibitors ([@B87]; [@B88]). Of the FDA-approved PARP inhibitors, veliparib is the least effective at PARP trapping, irrespective of the fact that its IC~50~ value is lower than that of niraparib (2 nM and 3.2 nM, respectively). Olaparib has a significantly more favorable IC~50~ than rucaparib (5 nM and 1.4 nM for olaparib and rucaparib, respectively), and they exhibit equal efficacy as PARP trapping agents. Talazoparib has the more favorable IC~50~ and functions as the best PARP trapping agent ([@B87]). Talazoparib's ability to trap PARP is likely due to its bulky structure and rigidly which contributes to a slow rate of dissociation ([@B117]; [@B88]; [@B101]). Recent combination trials have demonstrated new indications of PARP inhibitors in combination with other therapeutics, extending their use beyond cancers with BRCAness. One such example includes a combination therapy of rucaparib and temozolomide in metastatic melanoma, a cancer not typically associated with BRCA1/2 mutations ([@B99]).

PARP Inhibition as a Radiosensitizer {#s2_6}
------------------------------------

While PARP inhibition in cancers with "BRCAness" can induce synthetic lethality, PARPi in other cell lines can radiosensitize them. The PARPi 3-aminobenzamide was able to radiosensitize two breast cancer cell lines, MDA-MB-231 and MDA-MB-436, one with and one without BRCA mutation, respectively ([@B141]). The mechanism of PARPi induced radiosensitivity is most likely a DNA replication-dependent model in which replication forks collapse during delayed SSB repair, as demonstrated by Dungey et al. in which a replication-dependent increase in ɣH2AX foci in G2 cells was observed after treatment with olaparib and fractionated ionizing radiation (IR) in the T98G model of glioblastoma ([@B35]). Noel et al. showed HeLa cells were radiosensitized by the PARPi 4-amino-1,8-naphthalimide during S phase. Irradiation of these cells produced an increase of DSBs hours after irradiation ([@B89]). Evidence supporting a cell-cycle dependent effect was provided earlier by Chalmers et al. when hamster fibroblast cell lines V79-379A and CHO-K1 and human glioma cell line T98G treated with PARPis were the most radiosensitive during periods of rapid growth. Once cells had been arrested in G1 phase, radiosensitivity was lost ([@B24]).

Preclinical Models of Combination Therapies {#s3}
===========================================

*In Vitro*---Clonogenic Assays {#s3_1}
------------------------------

The Marples group out of Wayne State University has demonstrated that radiosensitivity can be increased through PARP inhibition in human glioma cell lines U373-MG and T98G. Clonogenicity was evaluated with increasing concentrations of PARP inhibitors (1--3 μM) that were found to be non-toxic in the absence of radiation. A 3 μM concentration of PARP inhibitor, the highest concentration of inhibitor that was non-toxic in the absence of IR, was then used in conjunction with low levels (0.05--0.3 Gy) of ionizing radiation (IR) to induce toxicity ([@B24]). Treatment with a small molecule PARP inhibitor, AG14361, followed by 8 Gy IR reduced survivability in colorectal cancer cell lines (LoVo) by 73% ([@B16]). Non-small cell lung cancer (NSCLC) cell lines A549 and Calu-6 were each treated with 1 μM and 5 μM of olaparib before being exposed to 0, 2, 4, and 6 Gy to find dose-dependent sensitization of both cell lines. For A549 and Calu-6 the Survival Enhancement Ratios (SER) values at 1 μM were found to be 1.3 and 1.5, respectively. These values increased to 1.6 μM and 1.8 at 5 μM ([@B115]). Veliparib was shown to have a limit on radiosensitization with concentrations above 2.5 μM no longer increasing radiosensitivity in a NSCLC cell line, H1299. Survival fractions were decreased when IR was supplemented by pretreatment of 2.5 μM veliparib. This effect was also observed in human prostate cancer cell lines (DU145 and 22Rv1) ([@B70]). The PARP inhibitor E7016 was able to increase radiosensitivity across multiple cancer cell lines as well. A dose enhance factor ≥1.4 was calculated for glioblastoma (U251) and pancreatic (MiaPaCa), and prostate cancer (DU145) cell lines when treated with E7016 prior to IR. Surviving fractions in all three cell lines were reduced to 0.1 in clonogenic assays ([@B109]). Veliparib demonstrated no effect on colony formation in PC-3 prostate cancer cells when incubated in 10 μM veliparib. The same treatment, followed by 2 Gy IR, reduced colony formation to 47% ([@B8]). 22Rv1 prostate cancer cells had PARylation reduced by 97--100% after incubation with the PARP inhibitor olaparib. The radiosensitization enhancement ratio was found to be ≥1.2 when combined with IR compared to PARP inhibitor alone. This result was found in acutely hypoxic, chronically hypoxic, and normoxic conditions ([@B43]). These works establish the efficacy of a variety of PARP inhibitors as radiosensitizers for multiple human cancer cell lines at low μM concentrations, often below cytotoxic concentrations of the PARP inhibitors themselves.

*In Vivo*---Tumor Growth Delay and Survival {#s3_2}
-------------------------------------------

Combination therapy is a more efficacious approach to treating H460 models of non-small cell lung cancer. A tumor growth delay assay using a five-fold increase in tumor volume as an endpoint saw a 1-day or 7-day delay using the PARP inhibitor veliparib or external beam radiation alone, respectively. When these therapies were combined, the five-fold increase in tumor volume was delayed by 13.5 days ([@B1]). A subcutaneous LoVo xenograft model of colorectal cancer exhibited tumor growth delay of 19 days with a fractionated regimen of IR that was increased to 37 days when combined with a low dose of AG14361, which did not delay tumor growth when administered alone ([@B16]). Tumor growth was significantly impeded in a dose-dependent trend of GPI-15427 and 2 Gy in mouse models of JHU006 and JHU012 HNSCC ([@B59]). A dose response dependency of veliparib was demonstrated in a human colon cancer mouse xenograft model, HCT116, when administered through a subcutaneously implanted osmotic pump in conjunction with IR compared to IR alone ([@B31]). Calu-6 mouse xenograft models received a daily 50 mg/kg dose of olaparib for 5 days, 5 days of 2 Gy IR daily, or both therapies. The combination therapy cohort experienced a significant delay of 10 days to reach the endpoint compared to either monotherapy or control cohort ([@B115]).

Mouse models of HCT116 colorectal cancer receiving twice daily orally administered doses of 12.5 mg/kg of veliparib in conjunction with 2 Gy fractions of IR displayed significant tumor growth delay compared to control groups of IR alone ([@B116]). Olaparib was also tested as a radiosensitizer in subcutaneous mouse models of glioblastoma-initiating cells. Daily treatment of olaparib over 7 days was administered concurrently with 3 Gy of IR every other day for three total doses to find greater tumor growth delay than vehicle, IR alone, or IR with vehicle ([@B133]). The effect of fractionated RT after sensitization by olaparib was evaluated in a 22Rv1 human prostate cancer mouse model. One cohort received a single 8 Gy dose on the third day of three consecutive daily doses of intraperitoneally administered PARP inhibitor. A second cohort was treated with seven consecutive days of olaparib, with 5 × 2 Gy doses every other day starting 3 days after the initial PARP inhibitor injection. The group receiving fractionated doses displaying a non-significant delay in tumor growth compared to the vehicle + fractionated IR control group ([@B43]). The above data suggests that a combination therapy between PARP inhibitors and RT is more effective *in vitro* and *in vivo* than either therapy alone and is summarized in [**Table 1**](#T1){ref-type="table"}.

###### 

Preclinical combination therapies with PARP inhibitors and ionizing radiation.

  PARPi                Disease        Cell line            Assay                Publication
  -------------------- -------------- -------------------- -------------------- -------------
  AG14361              Colorectal     LoVo                 Clonogenic           [@B16]
  Tumor growth delay                                                            
  E7016                Glioblastoma   U251                 Clonogenic           [@B109]
  Pancreatic           MiaPaCa                                                  
  Prostate             DU145                                                    
  GPI-15427            HNSCC          JHU006               Tumor growth delay   [@B59]
  Olaparib             NSCLC          A549                 Clonogenic           [@B115]
  Calu-6                                                                        
  Tumor growth delay                                                            
  Glioblastoma         GIC            Tumor growth delay   [@B133]              
  Prostate             22Rv1          Tumor growth delay   [@B43]               
  Clonogenic                                                                    
  PJ34                 Glioblastoma   U373-MG              Clonogenic           [@B24]
  T98G                                                                          
  Veliparib            NSCLC          H460                 Tumor growth delay   [@B1]
  JHU012                                                                        
  Colon                HCT116         Tumor growth delay   [@B31]               
  NSCLC                H1299          Clonogenic           [@B70]               
  Prostate             DU145                                                    
  22Rv1                                                                         
  Prostate             PC-3           Clonogenic           [@B8]                
  Tumor growth delay                                                            
  Colon                HCT116         Tumor growth delay   [@B116]              

Combination Therapy Clinical Trials {#s4}
===================================

Ionizing Radiation With Chemotherapy and PARPis {#s4_1}
-----------------------------------------------

There are currently several completed clinical trials exploring the efficacy of combining PARP inhibitors, radiotherapy and chemotherapy, none of which have available results. In a phase I study of patients with phase II or III rectal cancer, patients were given 825 mg/m^2^ capecitabine twice daily and 1.8 Gy fractions daily for a total of 50.4 Gy over approximately 6 weeks in conjunction with escalating doses (20--400 mg) of veliparib orally twice daily. Maximum tolerated dose was not reached, and the study found 400 mg twice daily to be the appropriate dose of veliparib for the phase II study (NCT01589419, [@B25]). Two other phase I studies evaluating the combination of veliparib and temozolomide against diffuse pontine glioma and glioblastoma have also concluded, but results have not yet been posted (NCT01514201, NCT00770471). The PARADIGM-2 study is two parallel phase I studies in which one arm evaluated dose escalation of olaparib (50--150 mg/daily) is combined with 60 Gy in 30 fractions over 3 weeks of radiotherapy followed by four additional weeks of olaparib. The second arm included the same regimen with concomitant temozolomide at 75 mg/m^2^ daily throughout radiotherapy and again after the 4 weeks of olaparib ([@B42]). One study aims to find the MTD of b 25--200 mg of olaparib twice daily beginning 3 days prior to the first dose of cetuximab. The initial 400 mg/m² dose of cetuximab will precede the start of radiation by 5--7 days. 69.3 Gy of radiation therapy will be administered in 33 fractions over 6.5 weeks (NCT01758731).

Ionizing Radiation With PARPis {#s4_2}
------------------------------

The first clinical trial exploring combination therapy between PARP inhibitors and ionizing radiation to publish results combines veliparib and whole brain radiation therapy (WBRT) in adult patients with brain metastases from non-small cell lung cancer (NCT00649207). Patients were age \>18 years with Karnofsky performance status (KPS) scores ≥70. One arm received WBRT administered daily in 2.5 Gy fractions over 15 sessions for 37.5 Gy total. A second arm was treated with 150 mg of veliparib twice daily with concurrent daily fractions of 3.0 Gy fractions over 2 weeks for 30 Gy.

All three arms of the study received a 30 Gy fractionated dose of 10 × 3 Gy doses, excluding weekends and holidays. The variable was the quantity of drug received twice daily: placebo, 50 mg veliparib, or 200 mg veliparib. The primary outcome was survival up to 36 months. While the patient tumor population was homogenous, 88--90% of patients in this trial had Graded Prognosis Assessment scores ≤2.5, amounting to an unfavorable prognosis, and the primary outcome was not met ([@B23]). It is worth noting that even when a combination therapy significantly prolongs survival in patient populations with favorable prognoses (GPA 2.5--4), it falls short of significance in populations with unfavorable prognoses ([@B7]). This study progressed to phase II (NCT01657799), where no benefit was found in combining WBRT with veliparib compared to WBRT and a placebo ([@B23]).

New Frontiers---PARPi Diagnostics and Radiotherapies {#s5}
====================================================

PARPi-FL {#s5_1}
--------

PARPi-FL was first reported in 2012 by the Weissleder Lab at Massachusetts General Hospital in human pancreatic cancer cells ([@B104]). It can be used for real-time visualization of intracellular kinetics of PARP inhibitors ([@B126]). It was later shown to be a viable imaging agent *in vivo* in a mouse model of glioblastoma ([@B52]). Composed of a BODIPY-FL dye conjugated to an olaparib scaffold, it retains a similar pharmacokinetic profile, including the low IC~50~ value of 12.2 nM compared to the 5.0 nM value of olaparib ([@B82]). It can also be blocked by pretreatment with olaparib. PARPi-FL uptake in tumors is rapid, with statistically significantly increased tumor-to-muscle and tumor-to-brain ratios of ≥10 in a mouse model of glioblastoma. Uptake of PARPi-FL was correlated to PARP1 expression, and increased after irradiation ([@B52]; [@B61]). Retention persists for hours, with \<50% metabolites present in the blood at peak uptake in tumors ([@B52]). PARPi-FL has been used for real-time measurements of drug--target interaction *in vitro* and *in vivo* ([@B33]; [@B34]). The translational potential of PARPi-FL was highlighted when high tumor-to-organ ratios were observed in an orthotopic model of oral squamous cell carcinoma using clinical imaging instruments ([@B61]; [@B20]), and early clinical outcomes have been reported \[NCT03085147 and ([@B63])\].

PARPi-Derived PET Tracers {#s5_2}
-------------------------

The first radiolabeled PARP inhibitor for PET imaging was designed to monitor tissue necrosis. The Mach Group at Washington University labeled the small molecule PARP1 inhibitor PJ34 with carbon-11 and had good yields with increased uptake in target tissue in a rat model of Type I diabetes ([@B128]). The first reported fluorine-18-labeled PARP inhibitor was \[^18^F\]FE-LS-75 from the Roesch Group at Johannes Gutenberg-University, which showed high yields up to 80% ([@B105]) but did not report *in vitro/vivo* experiments. The first fluorinated PARP-targeted small molecule based on a later FDA-approved PARP inhibitor was ^18^F-BO ([@B57]). Uptake was shown to correlate to PARP1 expression in breast cancer mouse models. A dose of olaparib prior to injection with ^18^F-BO was able to reduce uptake *in vivo*. Favorable uptake was also observed in pancreatic and ovarian cancer models ([@B104]) ([**Figures 2A, B**](#f2){ref-type="fig"}). ^18^F-PARPi-FL was developed as a dual modality PET/fluorescent imaging agent ([@B58]). PARP1-specific uptake was demonstrated in glioblastoma xenografts. Both modalities showed similar tumor-to-brain uptake ratios (PET, 9:1; fluorescence, 7:1) as determined by autoradiography and fluorescence microscopy ([@B17]). ^18^F-PARPi is an olaparib-based PET imaging agent that exhibits high specificity for PARP1 in mouse models of orthotopic glioblastoma, diffuse intrinsic pontine glioma, and small-cell lung cancer ([@B19]; [@B62]; [@B21]) ([**Figures 2C, D**](#f2){ref-type="fig"}). ^18^F-PARPi has potential to non-invasively monitor disease progression and is currently in phase I clinical trials \[([@B112]), NCT03631017\]. Wilson et al. has published the synthesis and *in vivo* biodistribution of a fluorine-18 isotopologue of olaparib. Pre-irradiation of the cells and tumors was shown to increase uptake of the compound in several pancreatic cancer cell lines ([@B138]). ^18^F-FluorThanatrace (^18^F-FTT) is a rucaparib-based PET imaging agent first published in a human breast cancer mode ([@B142]) ([**Figure 2E**](#f2){ref-type="fig"}). It was the first PARP-targeted PET imaging agent to be tested in the clinic and is currently involved in several phase I clinical trials, evaluating uptake in different cancers ([@B83]; [@B74]).

![*In vivo* PET/CT Imaging. **(A)** Correlation of ^18^F-BO uptake and PARP expression in two ovarian and two pancreatic tumor types as determined by immunoblotting. **(B)** Coronal and axial PET/CT scans of a subcutaneous A2780 tumor-bearing mouse ([@B104]). **(C)** Sagittal PET/CT images of orthotopic U251 MG tumor-bearing mice 2 h post-injection of ^18^F-PARPi. **(D)** PET/CT 2 h post-injection ^18^F-PARPi after 30 m pre-injection of 500-fold excess olaparib ([@B19]). **(E)**MicroPET images of MDA-MB-231 tumors in mice tumor at 60 min after ^18^F-FTT injection before and after treatment with olaparib (ip 50 mg/kg 20 min pretreatment; [@B142]). Reprinted by permission from Springer Nature: Springer Molecular Imaging and Biology ([@B19]) (Non-invasive PET imaging of PARP1 expression in glioblastoma models, Carney, B, G Carlucci, B Salinas, V Di Gialleonardo, S Kossatz, A Vansteene, VA Longo, A Bolaender, G Chiosis, KR Keshari, WA Weber, and T Reiner), copyright (2016).](fphar-11-00170-g002){#f2}

PARPi Radiotherapeutics {#s5_3}
-----------------------

Several PARP inhibitors have also been labeled with therapeutic isotopes ([@B110]; [@B53]; [@B103]; [@B75]; [@B97]). The pharmacokinetic profiles of several iodinated PARP inhibitors based on olaparib were explored in human glioblastoma models *in vitro* and *in vivo*. Various length linkers were evaluated using an olaparib scaffold and a small library of iodobenzoic acids. The compounds with the best pharmacokinetics were radioiodinated and evaluated in culture and orthotopic mouse models of human glioblastoma for PARP1 specificity ([@B110]). The rucaparib scaffold was also leveraged in the design and synthesis of alpha- and auger-emitting radiotherapeutics using copper-catalyzed halogenation of boronic esters ([@B103]; [@B75]). The efficacy of PARP-targeted radiotherapeutics was first published in subcutaneous mouse models of glioblastoma, and later in orthotopic models of human glioblastoma ([@B53]; [@B97]). Intratumoral injections were implemented to mimic Convection Enhanced Delivery (CED). A reporter cell line transduced from U87 cells was designed to respond to p53 activation, as well as cellular density. This allowed imaging of cell death following treatment with the iodinated PARP inhibitor. Therapeutic efficacy was evaluated in a tumor growth delay experiment that found a fractionated dose of the drug could significantly delay the endpoint of the study ([**Figure 3A**](#f3){ref-type="fig"}). Use of a CED-mimicking subcutaneous implant allowed approximately 9 Gy to be delivered to a brain-tumor-bearing mouse compared to 1 Gy in a healthy mouse ([@B53]) ([**Figures 3B, C**](#f3){ref-type="fig"}). These results were leveraged in the synthesis and validation of an Auger-electron emitting isotopologue. Uptake of the drug can be decreased by pretreatment with olaparib and proved lethal to cells at concentrations lower than that of olaparib (EC~50~ = 69 nm). The radiotheranostic proved efficacious in prolonging survival of treated mice, and intratumoral administration of the drug in mice bearing human brain tumor significantly increased survival compared to vehicle alone (p = 0.0094). Application of CED-mimicking implants replicated this effect in the same model (p = 0.0361, [@B97]) ([**Figures 3D, E**](#f3){ref-type="fig"}). High radiochemical yields (≥89%) were reported for halogenation of both olaparib and rucaparib scaffolds with astatine-211 and iodine-125 ([@B103]). Antitumor effects were observed using an astatinated PARP inhibitor in a mouse model of neuroblastoma. Favorable uptake was observed in the tumor after 2 h. A single dose of the alpha-emitting drug was able to significantly delay tumor growth and prolong survival against a control group ([@B75]) ([**Figures 3F, G**](#f3){ref-type="fig"}).

![PARP targeted radiotherapies. Radiolabeled PARP inhibitors in mouse models of cancer. **(A)** Survival plot and table of treatment groups with median survival of subcutaneous U87-p53 tumor-bearing mice. P = 0.0001. **(B)** SPECT/CT of orthotopic U87-p53 tumors during osmotic pump treatment of \[^131^I\]PARPi at 72 hours. **(C)** Calculated absorbed dose to brain\* during treatment. \*Brain and tumor have been considered together as a single organ in organ level dose calculation. ([@B53]). **(D)** Dosimetry of the subcutaneous pump model showing CT, phantom, and Monte Carlo simulation of dose accumulation in the tumor. **(E)** Kaplan--Meier survival study of pump implanted mice shows an improvement of survival of ^123^I-MAPi treated mice (n = 8) when compared to control (n = 8). \*P \< 0.05 ([@B97]). **(F)** Tumor growth and Kaplan--Meier curves for IMR-05 tumor**-**bearing mice **(F)** treated with single dose of 555 or 1,110 kBq of \[^211^At\]MM4 (control *vs*. 555 kBq and 1,110 kBq mixed linear model p \< 0.0001; control *vs*. 555 and 1,110 kBq survival Mantel**--**Cox test p \< 0.0001, 555 vs. 1,110 kBq not significant, **(G)** and single high dose of 1,480 kBq *vs*. a fractionated dose of 370 kBq twice weekly for a cumulative dose of 1,480 kBq (control *vs*. fractionated mixed linear model p \< 0.0001, fractionated *vs*. high dose not significant; survival Mantel**--**Cox test high dose *vs*. control p \< 0.0001, fractionated *vs*. control p \< 0.03 ([@B75]).](fphar-11-00170-g003){#f3}

Summary and Outlook {#s6}
===================

Since its discovery we have elucidated the multiple roles PARP1 plays in the cell. PARP inhibitors have given rise to promising new cancer therapies and treatment strategies. We have recently witnessed PARPis receive approval as monotherapies for several cancers, and are waiting on the next generation of these small molecules. Many research groups are already evaluating the potential of PARPis as radiosensitizing agents in preclinical models of combination therapies. PARPis are currently being applied in the clinic as radiosensitizing agents in addition to clinical trials using combination PARPis with chemotherapies and radiation. A handful of these small molecules have been labeled to create a new class of diagnostic and radiotherapeutic agents, several of which are currently in clinical trials. The broad versatility and applications of these PARPis are providing the research community with a new set of tools for diagnosis, patient stratification, and therapy in some of the most lethal cancers.
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